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Abstract
Background: Primary hyperparathyroidism (PHPT) is characterised by increased production of parathyroid hormone (PTH)
resulting in elevated serum calcium levels. The influence on bone metabolism with altered bone resorption is the most
studied clinical condition in PHPT. In addition to this, patients with PHPT are at increased risk of non-skeletal diseases, such
as impaired insulin sensitivity, arterial hypertension and increased risk of death by cardiovascular diseases (CVD), possibly
mediated by a chronic low-grade inflammation. The aim of this study was to investigate whether adipose tissue reflects the
low-grade inflammation observed in PHPT patients.
Methodology/Principal Findings: Subcutaneous fat tissue from the neck was sampled from 16 non-obese patients with
PHPT and from 16 patients operated for benign thyroid diseases, serving as weight-matched controls. RNA was extracted
and global gene expression was analysed with Illumina BeadArray Technology. We found 608 differentially expressed genes
(q-value,0.05), of which 347 were up-regulated and 261 were down-regulated. Gene ontology analysis showed that PHPT
patients expressed increased levels of genes involved in immunity and defense (e.g. matrix metallopeptidase 9, S100
calcium binding protein A8 and A9, CD14, folate receptor 2), and reduced levels of genes involved in metabolic processes.
Analysis of transcription factor binding sites present in the differentially expressed genes corroborated the up-regulation of
inflammatory processes.
Conclusions/Significance: Our findings demonstrate that PHPT strongly influences gene regulation in fat tissue, which may
result in altered adipose tissue function and release of pathogenic factors that increase the risk of CVD.
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Introduction
Primary hyperparathyroidism (PHPT) is one of the most
common endocrine disorders [1]. Worldwide PHPT is most often
seen in postmenopausal women [2] and in Scandinavia the
prevalence was found to be higher than 2% in elderly women
[3,4]. The diagnosis of PHPT is biochemically determined by
increased serum parathyroid hormone (PTH) levels leading to
increased concentrations of serum calcium. 85% of the cases of
PHPT are caused by a single, benign parathyroid adenoma.
Parathyroidectomy cures 90–95% of these patients, measured by
normalisation of PTH and calcium levels [5]. Elevated PTH levels
exert a well-described effect on bone metabolism, leading to
increased bone turnover and osteoporosis. Parathyroidectomy
reduces markers of bone turnover and increases bone density [6].
In the last decades there has been a shift in the clinical findings in
patients with PHPT. Due to improved diagnostic procedures and
analytical methods, mild PHPT is now often discovered in routine
health controls. Classical findings such as skeletal lesions and
nephrolitiasis have become rare.
Metabolic changes observed in patients with PHPT include
impaired insulin sensitivity, elevated LDL-cholesterol, decreased
HDL-cholesterol, and elevated circulating inflammatory markers
such as high-sensitive C-reactive protein and tumor necrosis
factor-alpha [7]. An increased risk of cardiovascular diseases
(CVD) in patients with PHPT has been reported [8]. In line with
this, patients with PHPT were shown to have an increased risk of
hypertension [9,10] and impaired glucose tolerance [11]. CVD
seems to be more evident in patients with severe PHPT, but also
PTH levels within the upper part of the normal range is associated
with an increased incidence of CVD [12]. Chronic low-grade
inflammation in PHPT may play an important role in the
development of CVD in these patients, since inflammation is a key
component in the pathogenesis of atherosclerosis [13].
Adipose tissue is an important endocrine organ with crucial
functions in the regulation of energy homeostasis, insulin
sensitivity, and lipid and carbohydrate metabolism [14]. Others
and we have described that adipose tissue in obesity shows a
marked increase in the expression of inflammatory genes and
release of adipocytokines [15,16]. To our knowledge the function
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7of adipose tissue has not been described in patients with PHPT.
Through global gene expression profiling we identified potential
risk genes with differential expression in subcutaneous adipose
tissue of non-obese PHPT patients compared to a weight-matched
control group. The most pronounced finding was an up-regulation
of inflammatory genes in PHPT patients while genes with
functions in fatty acid and carbohydrate metabolism were down-
regulated.
Materials and Methods
Ethics statement
The study war performed according to the principles expressed
in the declaration of Helsinki and all enrolled subjects signed an
informed written consent. The Western Norway Regional
Committee for Medical Research Ethics (REK) approved the
study.
Subjects and study design
The study included 16 patients (14 females and 2 males)
undergoing surgery for PHPT and 16 control subjects (11 females
and 5 males) operated for benign thyroid hypertrophy. Subjects
were recruited in the period from September 2007 to September
2009. Subcutaneous adipose tissue was obtained from the neck at
the beginning of the surgery. All patients were operated at the
Department of Endocrine Surgery, Haukeland University Hospi-
tal, Bergen, Norway. The diagnosis of hyperparathyroidism was
based on elevated serum PTH (ref. range: 1.3–6.8 pmol/L) and
ionised calcium levels (ref. range: 1.13–1.28 mmol/L). Exclusion
criteria were body-mass index (BMI).29 kg/m
2 and any kind of
known systemic inflammatory disease, such as inflammatory bowl
disease, rheumatological diseases and chronic obstructive lung
disease. Weight, height and medical history were recorded before
surgery.
Biochemical analysis
Blood samples were drawn the day before surgery from all
PHPT patients and within the first day after operation from the
control subjects. Ionised calcium, phosphate, creatinine, total
cholesterol, HDL-cholesterol and LDL-cholesterol were analysed
immediately by standard laboratory methods. PTH was measured
with a two-site chemiluminescent immunometric assay for intact
PTH (Immulite 2000, Siemens, UK). The inter-assay variation
was 6.3% at a concentration of 5.6 pmol/L and 8.8% at 40 pmol/
L.
Homogenisation and RNA extraction
Biopsies of subcutaneous adipose tissue obtained during surgery
were immediately frozen and stored in liquid nitrogen until
homogenisation and RNA extraction. Frozen adipose tissue was
transferred into 2 ml safe-lock eppendorf tubes with rounded
bottom. A 5 mm metal bead (Millipore, USA) and one ml quiazol
lysing buffer (Qiagen, Germany) were added and homogenisation
in a TissueLyser (Qiagen) followed immediately. RNA extraction
was performed using the RNeasy Lipid Tissue Midi Kit (Qiagen).
Samples were treated with the RNase-Free DNase Set and the
RNeasy MiniElute Cleanup Kit (Qiagen). Amount and quality of
the extracted RNA were measured by the NanoDropH ND-100
spectrophotometer (NanoDrop Technologies, USA) and the
Agilent 2100 Bioanalyzer (Agilent Technologies, USA).
Microarray analysis
Microarray analysis was performed using the Illumina Human-
Ref-8 v.3 Expression BeadChips, which targets about 24,500
annotated RefSeq transcripts and covers 18,631 unique curated
genes. In total, 32 microarrays from 16 biological replicates,
respectively 16 patients and 16 controls, were performed. 370 ng
of total RNA was used for the Illumina TotalPrep Amplification
Kit (version 27.07.09, Applied biosystems/Ambion, USA) to
generate biotin-labelled, amplified RNA. Quality of labelled
cRNA was measured using the NanoDropH ND-100 spectropho-
tometer and the Agilent 2100 Bioanalyzer. 750 ng biotin-labelled
cRNA was used for hybridisation to gene-specific probes on the
Illumina microarrays (product number BD-102.0203) according to
the Whole-Genome Gene Expression Direct Hybridization Assay
Guide (Illumina Inc, Nov 2006). The Illumina arrays were then
scanned with the iScan Reader, based on fluorescence detection of
the biotin-labelled cRNA. The Illumina microarray data are
MIAME compliant and the raw data have been deposited in the
database ArrayExpress (ArrayExpress accession: E-TABM-1119).
Analyses were performed at the Norwegian Microarray Consor-
tium (NMC) Core Facility, University of Bergen, Norway.
Microarray data extraction and analysis
Raw data were imported into the GenomeStudio Data Analysis
Software and quality controls were performed. Seven different
control categories were built into the Whole-Genome Gene
Expression Direct Hybridization Assay system, covering every
aspect of an array experiment. Looking at the technical controls in
GenomeStudio, one of the samples (sample C-111, a male control)
had a different distribution of signals in several control plots, such
as the box plot visualising the variation within an array and
between arrays, the line plot of detected genes, the line plot of
noise and the line plot of labelling control across samples. All
samples were included in further quality control, outlier detection,
and pre-processed using the J-Express software version 2009
(MolMine, Norway) [17]. Quality control and analysis in this
software was done on log2-transposed data. Correspondence
Analysis [18] and hierarchical clustering with Pearson Correlation
as a distance measure were used on both the un-normalised and
quantile normalised dataset [19]. The Correspondence Analysis
plot was used to look for greatest co-variance in the dataset.
Sample C-111 was an outlier in the un-normalised dataset in the
Correspondence Analysis plot, and together with the outlier
detection of control probes in GenomeStudio we decided to
exclude this sample before further analysis.
Significance Analysis of Microarrays (SAM) [20] was used to
look for differentially expressed genes, which were defined by q-
value,0.05. Protein Analysis Through Evolutionary Relationships
(PANTHER) (version 6.1, http://www.pantherdb.org) was used to
organise differentially expressed genes in categories representing
biological processes and molecular functions. We looked for over-
representation of differentially expressed genes in such categories,
relative to the expected representation in the whole genome. The
Bonferroni correction for multiple testing was used in the
calculation of p-values for the over-represented PANTHER
categories.
Validation of microarray data by qPCR
Nine genes of interest were selected for validation of the
microarray results by quantitative real time PCR (qPCR). qPCR
analyses were performed on all samples included in the study. The
SuperScript Vilo cDNA Synthesis Kit (Invitrogen GmbH,
Germany) was used for cDNA synthesis, followed by qPCR with
the LightCycler480 Probes Master kit and the LightCycler480
rapid thermal cycler system (Roche Applied Science, USA). Probes
and primers for target genes (Table 1) were designed using
Univeral ProbeLibrary (UPL) Assay Design Center (Roche
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one transcript variant (CD14 and FOLR2), primers and probes
were designed to cover all variants. The UPL human TATA box
binding protein (TBP) Gene Assay (Roche Applied Science) was
used for the reference gene. Target genes were amplified in duplex
with TBP except for IL8, CD14 and SCD since duplex affected
the amplification efficiency of their transcript. Instead, expression
levels were calculated relative to the mean TBP concentration
from four of the duplex runs. Data analysis was performed using
PASW Statistics 18 for Mac and the statistical package provided in
Excel (Microsoft). To assess differences between the two groups we
used the Mann-Whitney U Test. All tests were two-sided and
p,0.05 was considered to be statistically significant.
oPOSSUM binding site analysis
To analyse which transcription factors might regulate the
differentially expressed genes, we uploaded the lists of up- and
down-regulated genes to the oPOSSUM program online (http://
www.cisreg.ca/cgi-bin/oPOSSUM/opossum) [21]. oPOSSUM
uses a database of conserved transcription factor binding sites
(TFBS), and calculates significance values (Z-score and Fisher
score) for over-representation of TFBS in a list of co-expressed
genes. Transcription factors for which there are more binding sites
in the co-expressed genes than expected are over-represented. A
list of transcription factors predicted to regulate a significant
number of the co-expressed genes was retrieved. Top 10% of
conserved regions, 80% matrix match threshold, Z-score.5 and
Fisher score ,0.05 were chosen as output parameters (vertebrate
matrix).
Results
General data of the study population
The analysis included 31 individuals, thereof 16 PHPT patients
and 15 controls. Characteristics of the study population are listed
in Table 2. All patients had elevated serum PTH concentrations
due to a parathyroid adenoma. Six months after surgery all
patients had normalised serum PTH and ionised calcium levels.
One patient had serum PTH of 3.8 pmol/L (ref. range 1.3–
6.8 pmol/L). This patient had an elevated serum ionised calcium
level of 1.45 mmol/L (ref. range: 1.13–1.28 mmol/L), osteoporo-
sis and an adenoma in one of the parathyroid glands localised by
ultrasonography and scintigraphy. The diagnosis of an adenoma
in the parathyroid gland was histologically confirmed after
extirpation of the gland. Six months after operation this patient
had serum PTH of 2.8 pmol/L and serum ionised calcium was
normalised at 1.24 mmol/L. All control subjects had serum PTH
and calcium within the normal reference range. None of the
patients or controls had known diabetes mellitus or atherosclerotic
disease. Six of the patients with PHPT and one patient in the
control group used medication for hypertension.
To adjust for the influence of age and sex on our results we
selected a group of patients and controls including only females
aged 27–65 years. In the age- and gender-adjusted group the
average age for patients (n=9) was 52.8 years (range 28–64) and
48.4 years (range 30–60) for controls (n=9) (p=0.4). In the
subgroup there were not statistically significant differences in
phosphate (p=0.2) and ALP (p=0.067). LDL-cholesterol was
significantly higher in patients (3.660.44 mmol/L) than in
controls (2.860.63 mmol/L) (p=0.022). Levels of TSH, FT4,
creatinine, cholesterol and HDL-cholesterol were not different
between the groups.
Shift in global gene expression in PHPT patients
Microarray analysis revealed a difference in the adipose tissue
gene expression in patients with PHPT compared to controls.
Correspondence analysis showed that the two groups were
separated by distinct gene expression patterns, where the first
principal component represented 8.83% of the total variance and
the second principal component 6.69% (Fig. 1). Using Significance
Analysis of Microarray (SAM), we found 608 differentially
expressed genes with q-value,0.05, thereof 347 up-regulated
and 261 down-regulated genes in PHPT patients compared to the
control group. Several of the most up-regulated genes have
previously been implicated in inflammatory diseases whereas
many of the down-regulated genes play roles in lipid and
Table 1. Primers used in this study.
GeneBank ID Genes PCR primers (59-39) Probe nr (UPL) Product size (bp)
NM_004797.2 AdipoQ AGG GTG AGA AAG GAG ATC CAG
TCC TTT CCT TTG GAT T
41 113
NM_002982.3 CCL2 AGT CTC TGC CGC CCT TCT
GTG ACT GGG GCA TTG ATT G
40 93
NM_000591.2 (tv 1) NM_0010400211 (tv 2) CD14 GTT CGG AAG ACT TAT CGA CCA T
ACA AGG TTC TGG CGT GGT
74 95
NM_013402.4 FADS1 TCT CTC CTG ATT GGA GAA CTG TG
CCG GAA CTC ATC TGT CAG C
26 81
NM_004104.4 FASN CAG GCA CAC ACG CTG GAC
CGG AGT GAA TCT GGG TTG AT
11 92
NM_000803.4 (tv 1) NM_001113534.1 (tv 2)
NM_001113536.1 (tv 3) NM_001113535.1 (tv 4)
FOLR2 CTA TGA GTG CTC ACC CAA CCT
CCA GGA AGC GTT CTT TGC
81 74
NM_000584.2 IL8 AGA CAG CAG AGC ACA CAA GC
ATG GTT CCT TCC GGT GGT
72 62
NM_004994.2 MMP9 GAA CCA ATC TCA CCG ACA GG
GCC ACC CGA GTG TAA CCA TA
66 7
NM_005063.4 SCD CCT AGA AGC TGA GAA ACT GGT GA
ACA TCA TCA GCA AGC CAG GT
82 65
UPL, Universal ProbeLibrary probes (Roche Applies Science); tv, transcript variant.
doi:10.1371/journal.pone.0020481.t001
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only females aged 27–65 years we found 162 differentially
expressed genes with q-value,0.05. Of these, 113 genes were
up-regulated and 49 genes were down-regulated. Correspondence
Analysis of this age-matched subgroup showed equally marked
differences in gene expression, with first and second principle
component variance of 11.38% and 9.851%, respectively.
Increased inflammatory response and reduction of
metabolic processes
To gain further insight into the potential functions of the
differentially expressed genes, we analysed their ontology based on
PANTHER functional categories (Fig. 2). Analysis of the up-
regulated genes showed that the Biological Process categories
Immunity and defense (e.g. S100 calcium binding protein A9
(S100A9, Entrez gene 6280), S100 calcium binding protein A8
(S100A8, Entrez gene 6279), CD14 molecule (CD14, Entrez gene
929)) and Signal transduction (e.g. integrin, beta2/CD18 (ITGB2,
Entrez gene 3689), macrophage receptor with collagenous
structure (MARCO, Entrez gene 8685)) were strongly over-
represented in the PHPT patients compared to controls. Analysing
the down-regulated genes in PHPT patients we found an over-
representation of the Biological Process categories Lipid, fatty acid
and steroid metabolism (e.g. fatty acid synthase (FASN, Entrez
gene 2194), stearoyl-CoA desaturase (SCD, Entrez gene 6319)),
Coenzyme and prosthetic group metabolism (e.g. acetyl-CoA
carboxylase alpha (ACACA, Entrez gene 31), enoyl Ca-A hydratase
domain containing 1 (ECHDC1, Entrez gene 55862)), and
Carbohydrate metabolism (e.g. aldolase C, fructose-bisphosphate
(ALDOC, Entrez gene 230), citrate synthase (CS, Entrez gene
1431)). Over-represented Molecular Function categories for the
up-regulated genes included Defense/immunity protein (Comple-
ment component (e.g. CD55 molecule (CD55, Entrez gene 1604),
complement factor B (CFB, Entrez gene 629)), Immunoglobulin
receptor family member (e.g. leukocyte immunoglobuline-like
receptor, subfamily B, member 5 (LILRB5, Entrez gene 10990),
TYRO protein tyrosine kinase binding protein (TYROBP, Entrez
gene 7305)), Extracellular Matrix (e.g. matrix metallopeptidase 9
(MMP9, Entrez gene 4318), collagen, type VIII, alpha 2 (COL8A2,
Entrez gene 1296)), and Receptors (e.g. CD14, folate receptor 2
(FOLR2, Entrez gene 2350), colony stimulating factor 1 receptor
(CSF1R, Entrez gene 1436)). For the down-regulated genes there
Table 2. Anthropometric and biochemical measurements of the PHPT patient and control groups.
PHPT
(n=16, 14 female)
Control
(n=15, 11 female)
Median (IQR) Median (IQR) P-value
Age (years) 60.0 (49.3–69.2) 47.0 (38.0–56.0) 0.01
BMI (kg/m
2) 25.4 (23.5–27.2) 25.0 (22.9–26.9) 0.78
PTH (1.3–6.8 pmol/L) 11.5 (9.6–15.6) 3.3 (2.1–4.2) ,0.001
iCa (1.13–1.28 mmol/L) 1.47 (1.41–1.54) 1.24 (1.21–1.25) ,0.001
Phosphate (0.85–1.50 mmol/L) 0.87 (0.70–1.01) 1.08 (0.91–1.23) 0.02
ALP (35–105 U/L) 93.0 (74.0–119) 68.0 (51.5–82.0) 0.01
TSH (0.4–4.5 mIE/L) 1.40 (0.75–1.82) 1.12 (0.57–1.83) 0.90
FT4 (9.5–22.0 pmol/L) 16.6 (15.2–18.1) 17.8 (15.3–19.1) 0.45
Creatinine (45–90 umol/L) 60.5 (52.8–63.8) 69.5 (54.5–78.3) 0.24
Cholesterol (3.3–6.9 mmol/L) 5.6 (5.1–5.9) 4.7 (4.2–6.2) 0.23
LDL-cholesterol (1.8–5.7 mmol/L) 3.6 (3.2–3.9) 2.9 (2.5–3.9) 0.13
HDL-cholesterol (1.0–2.7 mmol/L) 1.5 (1.2–2.4) 1.5 (1.2–1.7) 0.68
Reference values are shown in parentheses. P-values are based on Mann-Whitney U test. PHPT, primary hyperparathyroidism; Control, patients operated for benign
thyroid disease without known parathyroid or inflammatory disease; IQR, interquartile range; BMI, body-mass index; iCa, ionised calcium; APL, alkaline phosphatase;
TSH, thyroid stimulating hormone; FT4, free thyroxin; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol.
doi:10.1371/journal.pone.0020481.t002
Figure 1. Correspondence analysis showing projection of
samples. Patients with primary hyperparathyroidism are shown with
red dots and the control group are shown with blue squares. The first
principal component shows the largest variance in the dataset with
8.83% and the second principal component represents the second
largest variance with 6.69%. Patients with primary hyperparathyroidism
are separated from the control group along both axes.
doi:10.1371/journal.pone.0020481.g001
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Lyase (e.g. carbonic anhydrase (CA4, Entrez gene 762), malic
enzyme 1 (ME1, Entrez gene 4199)) and Oxidoreductase (e.g.
SCD, Entrez gene 6319, FASN, Entrez gene 2194).
In principle the same categories of genes were differentially
expressed in the age-matched group of females aged 27–65 years
as in the entire dataset. Differentially up-regulated genes were
represented in the Biological Process groups Immunity and
defense and Signal transduction, and several of the up-regulated
genes in the whole group were also found significantly up-
regulated in the subgroup (e.g. S100A9, S100A8, MMP9, CD14
and LILRB5). As for the main group, the down-regulated genes in
the age-matched group were dominated by genes mapped to
metabolic processes, including lipid metabolism. Genes that were
differentially expressed in the main group showed similar mean
fold changes in the age-matched subgroup, though many of the q-
values for differentially regulated genes in the subgroup were
above 0.05. Possibly, the lack of significance for specific genes in
the age-matched subgroup may have been due to the reduced
sample size.
Validation of results by qPCR
The expression levels of nine selected genes of interest were
validated by real time qPCR (Table 4). The five up-regulated
genes (chemokine ligand 2 (CCL2, Entrez gene 6347), CD14,
FOLR2, IL8 and MMP9) were selected as representative genes of
inflammatory processes and the three down-regulated genes (fatty
acid desaturase 1 (FADS1, Entrez gene 3992), FASN and SCD) were
selected as representative genes of fatty acid and steroid
metabolism. In addition, adiponectin (ADIPOQ, Entrez gene
9370) was measured to verify a gene that was unchanged between
the patient and control group. Adiponectin is an adipokine that is
specifically expressed in and released from mature fat cells, and
that negatively correlates with BMI, insulin resistance, inflamma-
tion, and atherosclerosis [22]. The qPCR results were highly
consistent with the microarray results, showing significant
differences in expression for these genes between patients and
controls, except for adiponectin that was unchanged between the
groups (Table 4).
Analysis of transcription factor binding sites
To elucidate the transcriptional networks altered in the PHPT
group, we used the web-based program oPOSSUM to identify
frequent transcription factor binding sites in the differentially
expressed genes. Analysis of up-regulated genes showed a
significant enrichment of binding sites for the ETS class of
transcription factors (Spi-B transcription factor (Spi1/PU.1
related), GA binding protein transcription factor (GABPA), ETS
domain-containing protein Elk-1 (ELK1)), the basic leucine zipper
domaine (bZIP) transcription factor activator protein 1 (AP-1/
FOS), and the nuclear receptor RAR-related orphan receptor A
(RORA) (Z-score.5, Fischer score ,0.05) (Table 5). For the
down-regulated genes, there was a significant enrichment of
binding sites for the nuclear receptors estrogen receptor alpha
(ESR1) and hepatocyte nuclear factor 4, alpha (HNF4A), members
of the CTH2 zinc finger family (Myeloid zinc finger 1 (MZF1),
Sp1 transcription factor (SP1), ras responsive element binding
protein 1 (RREB1)), and the REL transcription factor NF-kappaB
Table 3. Top 10 up-regulated and down-regulated genes in patients with PHPT compared to controls, based on Significance
Analysis of Microarrays (SAM-analysis) (q-value,0.05).
Signal Intensity FC
Gene Definition PHPT Ctr PHPT/Ctr
S100A9 S100 calcium binding protein A9 (calgranulin B) 2429 699 3,13
S100A8 S100 calcium binding protein A8 (calgranulin A) 2367 660 2,97
MMP9 matrix metallopeptidase 9 647 229 2,55
CCL8 chemokine (C-C motif) ligand 8 2187 941 2,31
CSF3R colony stimulating factor 3 receptor (granulocyte), transcript variant 4 653 290 2,25
TYROBP tyrosine kinase binding protein, transcript variant 1 1917 693 2,20
ALOX5AP arachidonate 5-lipoxygenase-activating protein 2476 940 2,16
CCL13 chemokine (C-C motif) ligand 13 824 387 2,16
THBS1 thrombospondin 1 2133 1068 2,13
CD163 CD163 molecule, transcript variant 2 1295 450 2,11
FADS1 fatty acid desaturase 1 627 1461 22,18
CD300LG CD300 molecule-like family member g 6838 9423 21,76
KIF25 kinesin family member 25, transcript variant 1 394 598 21,74
ALDOC aldolase C, fructose-bisphosphate 6331 8326 21,72
SCD stearoyl-CoA desaturase (delta-9-desaturase) 18728 27771 21,68
CA4 carbonic anhydrase IV 2516 3334 21,66
THBS4 thrombospondin 4 2738 3779 21,66
PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B, transcript variant 2 2320 3908 21,66
GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 2882 3732 21,65
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 1107 1722 21,60
PHPT, primary hyperparathyroidism; Ctr, patients operated for benign thyroid disease without known parathyroid or inflammatory disease; FC, fold change (based on
log-transformed data).
doi:10.1371/journal.pone.0020481.t003
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20481Figure 2. Functional categorization of differentially expressed genes (Biological Process and Molecular Function). Gene expression in
subcutaneous adipose tissue in patients with primary hyperparathyroidism was compared to a control group. Over-represented Biological Processes
categories and Molecular Function categories among the differentially expressed genes (q-value,0.05) were found using PANTHER. Bonferroni
correction for multiple testing was done and a p-value,0.01 was used as inclusion criterion for categories. The colour intensity displays the statistical
significance (2log p-value) of over- and under-represented PANTHER functional categories. Numbers in the table presents the percentage of genes
mapping to a given category, e.g. 23% of the 347 up-regulated genes belonged to the Biological Process category Immunity and defense. The overall
distribution of a term among all human NCBI genes (25,431) are stated in the first column, e.g. 5% of the genes are expected to map to the Biological
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of the transcription factors themselves were not significantly
altered in PHPT patients compared to controls.
Discussion
Patients with PHPT are at increased risk of CVD, which may be
due to a chronic low-grade inflammation. In the present study we
investigated the gene expression profile of PHPT patients in
subcutaneous adipose tissue from the neck. Our results indicate
that patients with PHPT have inflammatory and metabolic
changes in their adipose tissue.
Pro-inflammatory stimuli alter the expression of adhesion
molecules on the endothelium, mediating endothelial attachment
of circulating lymphocytes and monocytes and initiating early steps
of atherosclerotic lesions [23]. It has previously been shown that
the subcutaneous adipose tissue in morbidly obese bariatric
patients expresses high levels of inflammatory genes, particularly
in stromal vascular cells [15,16]. Adipose tissue releases several of
these inflammatory factors in obese subjects, which may contribute
to elevated blood levels and diseases pathogenesis. Thus, it is
possible that the inflammatory changes we have observed in
adipose tissue of PHPT patients may result in increased circulating
levels of pro-inflammatory factors, thereby increasing the risk of
CVD.
S100A8 and S100A9 were the most up-regulated genes in the
adipose tissue of PHPT patients compared to controls. These
genes belong to a subgroup of the S100 family termed
calgranulins, which are highly expressed in monocytes. Calgranu-
lins mediate the induction of neutrophil chemotaxis and adhesion
and have an important role in tissue inflammation [24]. Elevated
levels of calgranulin are found in a wide range of acute and
chronic inflammatory diseases such as rheumatoid arthritis,
inflammatory bowl disease and asthma as well as in cancer [25].
It has been shown that calcium-mediated signalling is necessary for
the release of S100A8/A9 [26], suggesting that their expression
and possible release from adipose tissue may be increased due to
elevated calcium levels in PHPT patients.
Several genes encoding the complement cascade were up-
regulated in PHPT patients, including complement component 1
(C1) and the s-, q- and r- subcomponents of C1. The complement
cascade comprises more than 30 proteins produced by various cell
types, mainly hepatocytes but also monocytes and macrophages in
various tissues. Activation of the complement cascade is often
antibody-mediated, although antibody-independent mechanisms
can act as initiators. Cleavage of C1 into C1Q, C1R and C1S
further activates the cascade. This complement activation leads to
production of biologically active molecules contributing to
inflammation [27].
In our study MMP9 was one of the most up-regulated genes in
adipose tissue in PHPT patients compared to controls. Matrix
metallopeptidases (MMPs) are a family of zinc-dependent
endopeptidases involved in the degradation and reorganisation
of extracellular matrix [28]. Elevated circulating levels of MMP-9
may play a role in the development of hypertension [29] and
increased risk of death by CVD [30]. Moreover, MMP-9 has been
implicated in atherosclerosis and atherosclerotic plaque stains
positive for MMP-9 by immunhistochemistry [31]. In one study of
473 subjects, blood levels of MMP-9 were associated with grade of
atherosclerosis in the femoral artery [32]. The increased
expression of MMP9 in the adipose tissue of PHPT patients may
potentially contribute to the elevated risk of CVD.
An altered expression of monocyte/macrophage-related genes
appears to be a hallmark of adipose tissue inflammation. Several
studies have demonstrated an increased infiltration of pro-
inflammatory macrophages in adipose tissue in obese patients,
which may largely underlie the pathogenic potential of adipose
tissue [15,33]. Interestingly, our results indicate an increased
Table 4. Validation of selected genes by qPCR.
Illumina, Signal Intensity qPCR, Target gene/TBP
PHPT
(n=16)
Control
(n=15) q-value
PHPT
(n=16)
Control
(n=15) P-value
Median Median Median (range) Median (range)
ADIPOQ 2512 3182 0.191 1.69 (0.66–2.59) 1.75 (1.29–2.88) 0.252
CCL2 1404 638 0.066 0.54 (0.10–12.89) 0.19 (0.06–0.92) 0.016
CD14 2092 909 ,0.001 1.00 (0.25–3.22) 0.35 (0.18–0.72) ,0.001
FADS1 627 1461 0.029 0.45 (0.05–2.29) 1.18 (0.16–3.96) 0.040
FASN 19111 28686 0.028 2.35 (0.61–9.21) 4.58 (1.33–8.0) 0.016
FOLR2 970 423 0.054 0.47 (0.09–1.29) 0.15 (0.04–0.56) 0.001
IL8 307 190 0.109 1.02 (0.01–84.96) 0.08 (0.01–5.25) 0.022
MMP9 647 229 ,0.001 3.33 (0.22–11.54) 0.53 (0.06–2.51) 0.001
SCD 18728 27771 0.028 0.35 (0.05–1.75) 0.70 (0.19–2.13) 0.030
Signal intensity measured by Illumina and median values of target genes relative to the control gene TATA-binding protein (TBP) is shown. P-values are based on Mann-
Whitney U test. PHPT, primary hyperparathyroidism; Control, patients operated for benign thyroid disease without known parathyroid or inflammatory disease; q-value,
adjusted p-values found using an optimised false discovery rate (FDR) approach.
doi:10.1371/journal.pone.0020481.t004
Process category Immunity and defense, hence this category is significantly over-represented among the up-regulated genes in patients with PHPT
compared to controls. Ref, Reference (based on all human NCBI genes); PHPT patients with primary hyperparathyroidism; Ctr, patients operated for
benign thyroid disease without known parathyroid or inflammatory disease; Arrow up, up-regulated/higher expressed genes in patients with PHTP
compared to controls; Arrow down, down-regulated/less expressed genes in patients with PHPT compared to controls.
doi:10.1371/journal.pone.0020481.g002
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Macrophage related genes that were up-regulated in PHPT
patients included CCL2 /MCP-1 (monocyte chemoattractant
protein 1), FOLR2 and CD14. CCL-2 acts as an important
chemotactic substance that induces infiltration of monocytes into
adipose tissue [34]. CD14 is expressed on monocytes/macrophag-
es, and activated macrophages also express an increased level of
the FOLR2 [35]. The analysis of transcription factor binding sites
present in the differentially expressed genes suggested that many of
the up-regulated genes in PHPT might be targets of the ETS
transcription factors, which have an important role in the
regulation of inflammation [36]. Although mRNA levels of the
transcription factor themselves are not up-regulated in PHPT
patients compared to controls, the increase in genes with
promoters containing binding sites for certain transcription factors
possibly indicates an altered regulation by these factors. The ETS
factors SpiB (PU.1 related) and PU.1 bind to almost identical ETS
binding sites [37]. PU.1 may play an important role in the
macrophage-related signalling cascades [38]. Binding sites for the
cFOS/AP-1 transcription factor were also increased in our patient
group. It has been shown that the engagement of cFOS to binding
sites in macrophages up-regulates the expression of pro-inflam-
matory genes [39]. Together, our findings suggest that macro-
phage activation and infiltration contributed to the adipose tissue
inflammation in the PHPT patients.
Along with the increased inflammation, our results indicate that
metabolic processes are down-regulated in the adipose tissue of
PHPT patients. Both anabolic and catabolic pathways of lipid
metabolism seemed to be influenced. Our data suggest that
adipose tissue expression of genes that are important for normal
metabolic functions (e.g. SCD, FASN and FADS1) may be reduced
in patients with PHPT. Genes encoding lipogenic enzymes such as
FASN and ACACA are regulated by the transcription factors sterol
regulatory element binding proteins (SREBP) [40]. However,
mRNA levels of these transcription factors were not significantly
changed in adipose tissue of patients with PHPT compared to the
control group. It is worth noting that some of the metabolic genes
that were down-regulated in the main group have been linked with
altered insulin sensitivity and risk of CVD. Mice with a disruption
in SCD-1 (stearoyl-CoA desaturase 1) have reduced adiposity,
resistance to diet-induced weight gain, reduced hepatic steatosis,
and increased insulin sensitivity [41]. Despite the metabolically
beneficial effects, these mice developed atherosclerosis, possibly
due to a macrophage inflammatory response in the artery wall
[42]. In humans an increased SCD activity in adipose tissue was
found to correlate with enhanced insulin sensitivity [43]. Reduced
mRNA levels of FASN in human visceral adipose tissue were
shown to correlate with higher BMI and increased metabolic
dysfunction, as measured by elevated values of HbA1c, glucose
levels, triglyceride and homeostasis model assessment (HOMA-IR)
[44]. Together, the observations suggest that down-regulation of
metabolic genes in PHPT patients may confer, or at least reflect,
metabolic dysregulation.
The mechanisms that promote the altered gene expression
profile in PHPT patients may involve a combined effect of
elevated levels of PTH and calcium. Our gene expression data
showed that adipose tissue expresses the PTH receptor, suggesting
that PTH may directly induce inflammatory genes and metabolic
changes in adipose tissue. A direct action of PTH on 3T3-L1
adipocytes showed a dose-dependent decrease in insulin-stimulat-
ed glucose uptake [45]. Stimulation of osteoblasts with PTH leads
to an up-regulation of inflammatory proteins including interleu-
kins [46] and MMP-9 [47]. Microarray analyses performed on
parathyroid gland tissue, cultured in hypo- or hypercalcemic
medium, revealed a number of genes that were consistently up-
regulated or down-regulated [48]. Some of these calcium-induced
genes, such as CCL8, were similarly affected in patients with PHPT
in the present study. MMP9 and CFB were down-regulated in the
parathyroid gland tissue cultured in hypercalcemic medium, while
these genes were up-regulated in the adipose tissue of patients with
PHPT. This could be due to a suppression of PTH in the
hypercalcemic cultured tissue, rather than an effect of the elevated
calcium level [48]. Furthermore, the inflammatory and metabolic
responses in adipose tissue of PHPT patients may have been, at
least in part, secondary to the influence of PTH and calcium on
other tissues.
Table 5. Enrichment of transcription factor binding sites in the differentially expressed genes.
TF TF Class TF Supergroup BG hits BG non-hits TG hits TG non-hits Z-score
Fisher
score
TF binding site in upregulated genes
SPIB ETS vertebrate 13162 1988 274 28 15.02 0.026
GABPA ETS vertebrate 5381 9769 122 180 7.85 0.046
RORA_1 Nuclear receptor vertebrate 7024 8126 161 141 5.43 0.010
FOS bZIP vertebrate 9677 5473 208 94 5.22 0.041
ELK1 ETS vertebrate 10697 4453 229 73 5.02 0.026
TF binding sites in down-regulated genes
ESR1 Nuclear receptor vertebrate 439 14711 13 226 7.79 0.025
ELK1 ETS vertebrate 10697 4453 189 50 6.91 0.002
MZF1_1-4 Zn-finger, C2H2 vertebrate 13090 2060 216 23 6.90 0.041
SP1 Zn-finger, C2H2 vertebrate 9192 5958 170 69 6.36 0.001
NF-kappaB REL vertebrate 5960 9190 111 128 6.19 0.016
HNF4A Nuclear receptor vertebrate 5541 9609 112 127 5.92 0.001
RREB1 Zn-finger, C2H2 vertebrate 817 14333 20 219 5.69 0.037
TF, transcription factor; BG, background gene (expected randomly); TG, target gene.
doi:10.1371/journal.pone.0020481.t005
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was not perfectly age-matched with the control group. Inflamma-
tion and metabolic changes could possibly be influenced by age.
However, when analysing the microarray and qPCR data on age-
matched subgroups we found the same patterns of differential gene
regulation. Another limitation of the study is that circulating
inflammatory markers or biochemical parameters indicating
insulin resistance were not available. This could have given
additional information concerning the changes observed in this
study. It should also be noted that the control group consisted of
patients operated for benign thyroid diseases. For ethical reasons
these patients were the healthiest group possible to obtain as
controls for our study.
Our findings highlight potentially important non-skeletal effects
of elevated PTH levels in patients with PHPT. In recent years the
importance of increased cardiovascular risk factors in these
patients has been discussed. Our study shows highly significant
alterations in gene expression in adipose tissue of PHPT patients
compared to controls in regards to inflammatory and metabolic
processes. The data suggest an increase in monocyte/macrophage
activation in the adipose tissue. Elevated PTH and calcium may
directly mediate the alterations in adipose tissue gene expression,
which may in turn promote the release of pathogenic factors. Our
data shed new light on inflammatory and metabolic alterations in
adipose tissue in patients with PHPT that are independent of BMI,
and which may confer increased risk of CVD.
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